Jefferies cuts Ionis Pharmaceuticals stock price target on trial miss

Ionis Pharmaceuticals’ Phase 3 CARDIO-TTRansform trial failed to meet its primary efficacy endpoint in 1,432 patients, with no statistically significant cardiovascular benefit vs placebo. Jefferies cut its Ionis price target to $90 from $113 while keeping a Buy, after attributing the combo outcome to Tafamidis’s overperformance and emphasizing Tafamidis monotherapy for earlier-stage patients. Multiple firms followed with target cuts (BofA to $90, TD Cowen to $94, Oppenheimer to $92), though Street consensus remains Buy ($75–$130 range), supporting only a moderate negative read-through for the stock.

Analysis

The first-order loser is IONS, but the deeper damage is to the economics of combination development in ATTR-CM: if event rates are too low and background therapy is too effective, future trials need either cleaner enrichment or much larger sample sizes, which raises cost, delays readouts, and lowers the NPV of late-stage assets. That matters beyond this program because it makes “add-on” cardiology strategies less attractive versus drugs that can win on monotherapy and simpler endpoints.

The relative winners are ALNY and BBIO, but for different reasons. ALNY benefits from a cleaner “single-agent with hard outcomes” narrative, while BBIO benefits if the market shifts toward agents that do not need to prove incremental benefit on top of strong baseline therapy. In the next 1-3 months, expect sell-side models to keep trimming IONS peak sales and probability-adjusted pipeline value, while ALNY/BBIO can continue to absorb incremental capital as the market rotates toward lower-ambiguity read-throughs.

Contrarian take: the market may still be underpricing how much this changes platform perception. The issue is not just one failed study; it is a higher bar for every future combo trial in a low-event-rate orphan market, which compresses the strategic value of partnering and can slow BD conversations. The main falsifier for the bearish IONS view is a sharp rebound in sentiment driven by updated subgroup analysis, a compelling biomarker story, or a credible new Phase 3 design that materially improves power assumptions; absent that, the stock can stay structurally discounted for months.

Key Decisions for Investors

• Long ALNY / short IONS as a 1-3 month relative-value pair: thesis is that the market will reward the cleaner monotherapy winner and continue to de-rate the failed combo story. Enter on any post-event stabilization; cut if IONS reclaims the pre-gap level and holds for several sessions.
• Overweight BBIO versus IONS for a 2-6 week catalyst window: BBIO has the better chance of becoming the default capital recipient in ATTR-CM if investors conclude combination add-ons are harder to prove. Falsifier: if management commentary or updated data shows the failure is clearly molecule-specific rather than class-specific.
• Avoid buying IONS on the first bounce; wait for consensus target cuts to wash through over the next 1-2 earnings cycles. If the stock cannot recover above the low-70s, treat rallies as sellable until a new catalyst resets expectations.
• Watch ALNY/BBIO implied vol for a call-spread expression rather than outright stock if options are liquid: the read-through can persist into conference season, but position sizing should be modest because the move is valuation-supported, not a guaranteed fundamental step-function.